Recursion (RXRX) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
58.5M
Gross Profit
13.2M
22.65%
Operating Income
-479.0M
-818.98%
Net Income
-463.7M
-792.75%
Balance Sheet Metrics
Total Assets
1.4B
Total Liabilities
413.8M
Shareholders Equity
1.0B
Debt to Equity
0.40
Cash Flow Metrics
Operating Cash Flow
-364.5M
Free Cash Flow
-376.2M
Revenue & Profitability Trend
Recursion Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 58.5M | 43.9M | 39.7M | 10.0M | 3.4M |
| Cost of Goods Sold | 45.2M | 42.6M | 48.3M | 0 | 0 |
| Gross Profit | 13.2M | 1.3M | -8.6M | 10.0M | 3.4M |
| Operating Expenses | 492.3M | 351.3M | 237.1M | 192.8M | 88.0M |
| Operating Income | -479.0M | -350.1M | -245.7M | -182.8M | -84.6M |
| Pre-tax Income | -464.8M | -332.1M | -239.5M | -186.5M | -87.0M |
| Income Tax | -1.1M | -4.1M | 0 | 0 | - |
| Net Income | -463.7M | -328.1M | -239.5M | -186.5M | -87.0M |
| EPS (Diluted) | - | -$1.58 | -$1.36 | -$1.49 | -$0.77 |
Income Statement Trend
Recursion Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 714.3M | 438.1M | 569.8M | 534.7M | 266.4M |
| Non-Current Assets | 734.3M | 215.6M | 131.5M | 75.6M | 32.1M |
| Total Assets | 1.4B | 653.7M | 701.3M | 610.3M | 298.6M |
| Liabilities | |||||
| Current Liabilities | 187.5M | 93.2M | 100.3M | 46.7M | 23.1M |
| Non-Current Liabilities | 226.3M | 97.1M | 115.2M | 20.7M | 481.8M |
| Total Liabilities | 413.8M | 190.3M | 215.5M | 67.4M | 504.9M |
| Equity | |||||
| Total Shareholders Equity | 1.0B | 463.4M | 485.8M | 542.9M | -206.3M |
Balance Sheet Composition
Recursion Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -463.7M | -328.1M | -239.5M | -186.5M | -87.0M |
| Operating Cash Flow | -364.5M | -298.4M | -86.3M | -172.8M | -53.7M |
| Investing Activities | |||||
| Capital Expenditures | -13.7M | -12.0M | -37.1M | -39.8M | -5.8M |
| Investing Cash Flow | 263.4M | -9.6M | 193.5M | -271.7M | -7.8M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 296.0M | 127.3M | 143.6M | 450.1M | 251.9M |
| Free Cash Flow | -376.2M | -300.3M | -120.9M | -198.4M | -52.1M |
Cash Flow Trend
Recursion Key Financial Ratios
Valuation Ratios
Forward P/E
-3.02
Price to Book
2.27
Price to Sales
35.49
PEG Ratio
-3.02
Profitability Ratios
Profit Margin
22.65%
Operating Margin
-1,297.85%
Return on Equity
-86.10%
Return on Assets
-38.51%
Financial Health
Current Ratio
4.11
Debt to Equity
9.95
Beta
0.83
Per Share Data
EPS (TTM)
-$1.80
Book Value per Share
$2.30
Revenue per Share
$0.19
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| rxrx | 2.1B | - | 2.27 | -86.10% | 22.65% | 9.95 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 1.9B | 2.89 | 1.32 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.